Results 81 to 90 of about 16,960 (244)

Circadian Immunity and Vascular Inflammation in Cardiovascular Disease Chronotherapy Windows: Time for a Re‐Assessment

Med Research, EarlyView.
ABSTRACT Circadian rhythms orchestrate cardiovascular physiology by regulating immune and inflammatory pathways. Disruption of these rhythms profoundly alters vascular homeostasis, thereby promoting the onset and progression of cardiovascular diseases (CVD).
Tian Zhang, Ge Zhang, Tian‐Ding Liu, Tianshu Gu, Fengyi Yu, Pengyuan Xu, Wunan Mi, Xuanjiang Zhao, Qian Guo, Honglin Zheng, Taiqi Zhao, Qiang Li, Di Lu, Mingxuan Duan, Chaoyang Yu, Ruhao Wu, Shiqian Zhang, Haonan Zhang, Zeyu Wang, Youyang Zheng, Yan Xiao, Zenglei Zhang, Ge Zhang   +22 more
wiley   +1 more source

Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study).

HYPERTENSION, 2019
Mineralocorticoid receptors (MRs) are implicated in the pathology of hypertension. MR blockers are recommended for the treatment of salt-sensitive or resistant hypertension.
S. Ito, H. Itoh, H. Rakugi, Y. Okuda, M. Yoshimura, Satoru Yamakawa   +5 more
semanticscholar   +1 more source

Cost-Effectiveness of Eplerenone in Patients with Left Ventricular Dysfunction after Myocardial Infarction—An Analysis of the EPHESUS Study from a Swiss Perspective [PDF]

, 2018
Objective: The EPHESUS study demonstrated that aldosterone blockade with eplerenone decreased mortality in patients with left ventricular systolic dysfunction (LVSD) and heart failure after acute myocardial infarction (AMI).
Burnier, Michel, Erne, Paul, Holm, Majbrit, Schwenkglenks, Matthias, Szucs, Thomas, Weintraub, William, Zhang, Zefeng   +6 more
core  

Drug treatment of hypertension: focus on vascular health [PDF]

, 2016
Hypertension, the most common preventable risk factor for cardiovascular disease and death, is a growing health burden. Serious cardiovascular complications result from target organ damage including cerebrovascular disease, heart failure, ischaemic heart
Cameron, Alan C., Lang, Ninian N., Touyz, Rhian M.   +2 more
core   +1 more source

Eplerenone nanocrystals engineered by controlled crystallization for enhanced oral bioavailability

Drug Delivery, 2021
Poor aqueous solubility of eplerenone (EPL) is a major obstacle to achieve sufficient bioavailability after oral administration. In this study, we aimed to develop and evaluate eplerenone nanocrystals (EPL-NCs) for solubility and dissolution enhancement.
M. A. Khan, Muhammad Mohsin Ansari, S. Arif, Abida Raza, Ho-Ik Choi, Chang-Wan Lim, Ha-Yeon Noh, Jin-Su Noh, S. Akram, H. A. Nawaz, M. Ammad, A. Alamro, A. Alghamdi, Jin-Ki Kim, A. Zeb   +14 more
semanticscholar   +1 more source

Risk factors for the development of subretinal fluid in the fellow eyes of patients with chronic central serous chorioretinopathy

Acta Ophthalmologica, EarlyView.
Abstract Purpose To assess the risk of subretinal fluid (SRF) development in the fellow eye of chronic central serous chorioretinopathy (cCSC) patients with unilateral SRF at baseline. Methods Medical records of 334 presumed cCSC patients were retrospectively reviewed.
Helena M. A. Feenstra, Tahir Cakar, Joost Brinks, Camiel J. F. Boon, Elon H. C. van Dijk   +4 more
wiley   +1 more source

Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis

BMC Cardiovascular Disorders
Background Eplerenone and spironolactone, recognized as mineralocorticoid receptor antagonists (MRAs), have been reported to improve clinical prognosis among individuals diagnosed with heart failure (HF).
Ahmed Elshahat, Ahmed Mansour, Mohamed Ellabban, Ahmed Diaa, Atef Hassan, Ahmed Fawzy, Omar Abdulrahman Saad, Moaz Abouelmagd, Mahmoud Eid, Ahmed Elaraby, Mohamed Hamouda Elkasaby, Ahmed Abdelaziz   +11 more
doaj   +1 more source

Long‐term follow‐up of chronic central serous chorioretinopathy patients receiving oral eplerenone and half‐dose photodynamic therapy in the SPECTRA trial: SPECTRA trial report No. 4

Acta Ophthalmologica, EarlyView.
Abstract Purpose Assessing the 24‐month treatment outcome of half‐dose photodynamic therapy (PDT) or oral eplerenone in chronic central serous chorioretinopathy (cCSC). Methods Multicentre randomized clinical trial included cCSC patients from the SPECTRA trial who were randomized to receive half‐dose PDT or oral eplerenone.
Helena M. A. Feenstra, Issam El Mansori, Thomas J. van Rijssen, Roula Tsonaka, Roselie M. H. Diederen, Carel B. Hoyng, Reinier O. Schlingemann, Camiel J. F. Boon, Elon H. C. van Dijk   +8 more
wiley   +1 more source

Eplerenone Improves Pulmonary Vascular Remodeling and Hypertension by Inhibition of the Mineralocorticoid Receptor in Endothelial Cells

HYPERTENSION, 2021
Supplemental Digital Content is available in the text. Pulmonary hypertension is characterized by progressive remodeling of the pulmonary arteries, however, this is not therapeutically targeted yet. Aldosterone and the MR (mineralocorticoid receptor) are
Jessica Kowalski, L. Deng, Chiara Suennen, D. Koca, David Meral, C. Bode, L. Hein, A. Lother   +7 more
semanticscholar   +1 more source

The development of type 2 diabetes amongst sibling pairs in the South‐South region of Nigeria: The effect of genetics, environment and lifestyle

Diabetic Medicine, EarlyView.
Abstract Introduction Type 2 diabetes is a complex condition with a multifactorial pathogenesis. The pathogenesis is considered to be polygenic due to complex interactions between genetic/epigenetic and environmental factors. The aim of this study is to determine the genetic, environmental and lifestyle factors associated with the development of type 2
Sunny Chinenye, Ibi Erekosima, Adrian H. Heald, Gesiye Bozimo, Simon G. Anderson, Samuel Seidu, Kariba Akhidue, Adaeze Ugwu, Chioma Unachukwu, Ibitrokoemi Korubo, Kingsley Chukwuemeka Patrick‐Iwuanyanwu, Victoria Gomba, Uwoma Batubo, Victoria Akanatei, Victor Ken‐Uba, Iyeopu Siminialayi, Sokiprim Akoko, Justin Ideozu, Hamilton Opurum   +18 more
wiley   +1 more source